Showing 1 to 12 of 13 results
US Foreign Aid Cuts Threaten HIV Prevention Efforts in Kenya
Reduced US funding for HIV programs in Kenya jeopardizes access to crucial preventative medications like PrEP and condoms for serodiscordant couples, leaving them vulnerable to infection.
US Foreign Aid Cuts Threaten HIV Prevention Efforts in Kenya
Reduced US funding for HIV programs in Kenya jeopardizes access to crucial preventative medications like PrEP and condoms for serodiscordant couples, leaving them vulnerable to infection.
Progress
20% Bias Score
EU Approves Twice-Yearly HIV Prevention Injection
The European Commission approved Lenacapavir (Yeytuo), a twice-yearly HIV prevention injection, following a positive EMA recommendation and successful clinical trials showing 100% effectiveness; this comes amidst a rise in HIV cases in the EU and global efforts to combat the disease.
EU Approves Twice-Yearly HIV Prevention Injection
The European Commission approved Lenacapavir (Yeytuo), a twice-yearly HIV prevention injection, following a positive EMA recommendation and successful clinical trials showing 100% effectiveness; this comes amidst a rise in HIV cases in the EU and global efforts to combat the disease.
Progress
48% Bias Score
Spain's PrEP Program Expands to Pharmacies, Reaching 30,000 Users
Spain's PrEP (HIV pre-exposure prophylaxis) program, launched in November 2019, has reached 30,000 users, mostly LGBTQ+ individuals, and is transitioning to pharmacy distribution to improve access and integrate broader sexual health services, including STI testing and addressing chemsex.
Spain's PrEP Program Expands to Pharmacies, Reaching 30,000 Users
Spain's PrEP (HIV pre-exposure prophylaxis) program, launched in November 2019, has reached 30,000 users, mostly LGBTQ+ individuals, and is transitioning to pharmacy distribution to improve access and integrate broader sexual health services, including STI testing and addressing chemsex.
Progress
44% Bias Score
Annual HIV-Prevention Injection Shows Promise in Phase 1 Trial
A phase 1 trial showed a single intramuscular injection of lenacapavir provided effective HIV prevention for at least 56 weeks in 40 participants, potentially revolutionizing PrEP access and adherence, with a semiannual version under regulatory review.
Annual HIV-Prevention Injection Shows Promise in Phase 1 Trial
A phase 1 trial showed a single intramuscular injection of lenacapavir provided effective HIV prevention for at least 56 weeks in 40 participants, potentially revolutionizing PrEP access and adherence, with a semiannual version under regulatory review.
Progress
44% Bias Score
Lenacapavir: Science's 2024 Breakthrough in HIV Prevention
Science magazine named the injectable HIV prevention drug lenacapavir its 2024 breakthrough; 99.9% effective in preventing HIV in clinical trials among men who have sex with men and transgender individuals, offering a six-month dosage alternative to daily oral PrEP, pending FDA (2025) and European a...
Lenacapavir: Science's 2024 Breakthrough in HIV Prevention
Science magazine named the injectable HIV prevention drug lenacapavir its 2024 breakthrough; 99.9% effective in preventing HIV in clinical trials among men who have sex with men and transgender individuals, offering a six-month dosage alternative to daily oral PrEP, pending FDA (2025) and European a...
Progress
32% Bias Score
Lenacapavir: A Breakthrough in HIV Prevention
Two large clinical trials showed lenacapavir, a twice-yearly injection, to be 96–100% effective in preventing HIV, exceeding daily oral PrEP's real-world effectiveness; this breakthrough could significantly curb the global HIV epidemic, though access challenges remain.
Lenacapavir: A Breakthrough in HIV Prevention
Two large clinical trials showed lenacapavir, a twice-yearly injection, to be 96–100% effective in preventing HIV, exceeding daily oral PrEP's real-world effectiveness; this breakthrough could significantly curb the global HIV epidemic, though access challenges remain.
Progress
52% Bias Score
EU Approves Twice-Yearly HIV Prevention Injection
The European Commission approved lenacapavir, a twice-yearly HIV prevention injection, showing 100% effectiveness in clinical trials; it will be launched as 'Yetto' across the EU and several other countries, addressing the rising HIV cases (24,700 new infections in 2023, a 11.8% increase) while faci...
EU Approves Twice-Yearly HIV Prevention Injection
The European Commission approved lenacapavir, a twice-yearly HIV prevention injection, showing 100% effectiveness in clinical trials; it will be launched as 'Yetto' across the EU and several other countries, addressing the rising HIV cases (24,700 new infections in 2023, a 11.8% increase) while faci...
Progress
40% Bias Score
EU Approves Twice-Yearly HIV Prevention Injection
European regulators approved Gilead's lenacapavir, a twice-yearly HIV prevention injection, 100% effective in trials, offering a significant advancement amid rising HIV cases (24,700 new diagnoses in 2023, up 11.8% from 2022).
EU Approves Twice-Yearly HIV Prevention Injection
European regulators approved Gilead's lenacapavir, a twice-yearly HIV prevention injection, 100% effective in trials, offering a significant advancement amid rising HIV cases (24,700 new diagnoses in 2023, up 11.8% from 2022).
Progress
40% Bias Score
Annual Lenacapavir Injection Shows Promise in HIV Prevention
A phase 1 study shows that a single annual injection of lenacapavir, an HIV antiviral drug, resulted in blood concentrations sufficient to potentially prevent HIV infection, offering a promising new approach to prevention.
Annual Lenacapavir Injection Shows Promise in HIV Prevention
A phase 1 study shows that a single annual injection of lenacapavir, an HIV antiviral drug, resulted in blood concentrations sufficient to potentially prevent HIV infection, offering a promising new approach to prevention.
Progress
44% Bias Score
Lenacapavir: 99.9% Effective HIV Prevention in Clinical Trials
Lenacapavir, a new HIV drug, demonstrated 99.9% effectiveness in preventing infection in a recent study of over 2,000 participants across diverse genders, representing a significant advancement in PrEP and potentially revolutionizing HIV prevention strategies.
Lenacapavir: 99.9% Effective HIV Prevention in Clinical Trials
Lenacapavir, a new HIV drug, demonstrated 99.9% effectiveness in preventing infection in a recent study of over 2,000 participants across diverse genders, representing a significant advancement in PrEP and potentially revolutionizing HIV prevention strategies.
Progress
48% Bias Score
Lenacapavir: Six-Monthly HIV Prevention Injection Named "Science" Breakthrough of the Year
"Science" magazine selected Lenacapavir, a six-monthly HIV-prevention injection, as its 2024 Breakthrough of the Year due to its superior efficacy and convenience compared to daily pills, potentially impacting global HIV prevention efforts.
Lenacapavir: Six-Monthly HIV Prevention Injection Named "Science" Breakthrough of the Year
"Science" magazine selected Lenacapavir, a six-monthly HIV-prevention injection, as its 2024 Breakthrough of the Year due to its superior efficacy and convenience compared to daily pills, potentially impacting global HIV prevention efforts.
Progress
36% Bias Score
Semiannual HIV Injection Shows High Efficacy, Poses Access Challenges
A Phase 3 trial shows Lenacapavir, a semiannual HIV prevention injection, is highly effective and comparable to daily Truvada, offering improved adherence and reducing stigma in high-prevalence regions, but its high cost poses a global access challenge.
Semiannual HIV Injection Shows High Efficacy, Poses Access Challenges
A Phase 3 trial shows Lenacapavir, a semiannual HIV prevention injection, is highly effective and comparable to daily Truvada, offering improved adherence and reducing stigma in high-prevalence regions, but its high cost poses a global access challenge.
Progress
40% Bias Score
Showing 1 to 12 of 13 results